New Cases of Clade I Mpox and Hantavirus Monitoring in the U.S.
Recent reports from the Centers for Disease Control and Prevention (CDC) confirm the presence of clade I mpox, a more aggressive type of the monkeypox virus, in the United States. At the same time, global health organizations are keeping an eye on newly identified hantavirus cases in Europe.
On Wednesday, the Connecticut Department of Public Health (CDPH) identified the state’s first case of clade I mpox in an individual who had recently traveled to Western Europe, where health officials are actively tracking infectious disease trends.
In a related note, the World Health Organization (WHO) has also flagged new hantavirus cases in Spain and France. This rare but significant illness can lead to severe respiratory issues in infected individuals.
Typically, hantaviruses spread through interactions with infected rodents, and while serious, these cases remain uncommon, according to WHO. Health professionals maintain that the current mpox situation “does not pose a risk to the general public,” yet they recommend the JYNNEOS vaccine for those deemed at risk.
First U.S. Case of New MPOX Strain
Symptoms associated with mpox include fever, swollen lymph nodes, and a distinctive rash, the CDC notes. Dr. Manisha Jutani, the CDPH Director, emphasizes the importance of vaccination, especially as summer festivities and travel commence. She stated, “The vaccine is safe, effective, and widely available. Completing both doses is the best way to protect yourself and your partner.”
Hantavirus and Its Risks
It’s worth mentioning a recent incident involving hantavirus on a cruise ship, which underscores the dangers associated with diseases linked to rodents. According to the CDC and WHO, clade I and clade II mpox are genetically distinct, and they differ notably in severity and geographic distribution.
Clade I has historically been traced back to Central Africa, associated with more severe health outcomes and higher mortality rates, often manifesting with extensive rashes and complications. In contrast, clade II is more common in West Africa and usually involves milder symptoms.
The CDC and WHO believe that understanding the differences between these two clades is crucial for assessing risks, especially with the uptick in international travel.
